UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook

Livanova

05/08/2026 11:11

Overview
UK medical technology firm's Q2 revenue grew 10.8%, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year 2026 revenue and adjusted EPS guidance

Outlook
LivaNova raises 2026 revenue growth guidance to 8%-9% on constant-currency basis
Company now expects 2026 adj diluted EPS of $4.30-$4.40
LivaNova lowers 2026 adj free cash flow guidance to $140 mln-$160 mln

Result Drivers
CARDIOPULMONARY SALES - Q2 Cardiopulmonary revenue rose, driven by growth in Europe, Essenz Perfusion System sales, strong consumables demand, and favorable realized price
NEUROMODULATION GROWTH - Q2 Neuromodulation revenue grew across all regions, driven by volume growth and favorable realized price
SUPPLY AGREEMENT - Co entered long-term agreement with Thermo Fisher Scientific to increase oxygenator component availability and expand manufacturing output

Company press release: ID:nBw6xkGmVa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$390.60 mln
$380.76 mln (9 Analysts)
Q2 Adjusted EPS
Beat
$1.26
$1.10 (9 Analysts)
Q2 EPS
 
$1.93
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for LivaNova PLC is $84.00, about 1.6% below its August 4 closing price of $85.33
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
Aug 4 - UK's Smith+Nephew cuts 2026 revenue view on weak US knee implant demand
Aug 3 - ClearPoint Neuro Q2 revenue rises 18% but misses estimates
Aug 3 - Integer Holdings Q2 sales fall 2.6%; KKR to buy company for $5.7 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)